MAIA (MAIA Biotechnology) Ending Cash Position : $9.60 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology Ending Cash Position?

MAIA Biotechnology's Ending Cash Position for the quarter that ended in Dec. 2024 was $9.60 Mil.

MAIA Biotechnology's quarterly Ending Cash Position declined from Jun. 2024 ($11.58 Mil) to Sep. 2024 ($8.69 Mil) but then increased from Sep. 2024 ($8.69 Mil) to Dec. 2024 ($9.60 Mil).

MAIA Biotechnology's annual Ending Cash Position declined from Dec. 2022 ($10.95 Mil) to Dec. 2023 ($7.15 Mil) but then increased from Dec. 2023 ($7.15 Mil) to Dec. 2024 ($9.60 Mil).

MAIA Biotechnology Ending Cash Position Historical Data

The historical data trend for MAIA Biotechnology's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology Ending Cash Position Chart

MAIA Biotechnology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

0.66

10.57

10.95

7.15

9.60

MAIA Biotechnology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial												7.15	8.27	11.58	8.69	9.60

MAIA Biotechnology Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

MAIA Biotechnology's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	7.15	+	2.451
	=	9.60

MAIA Biotechnology's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	8.691	+	0.91
	=	9.60

MAIA Biotechnology Ending Cash Position Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

MAIA Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

444 West Lake Street, Suite 1700, Chicago, IL, USA, 60606

Website

https://www.maiabiotech.com

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Executives

Stan Smith	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ramiro Guerrero	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Steven M Chaouki	director	C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Cristian Luput	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie	director, 10 percent owner	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc	director, 10 percent owner, officer: Chief Executive Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire	officer: Chief Financial Officer	6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Jean-manasse Theagene	director	500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Sergei Gryaznov	officer: Chief Scientific Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea	officer: Chief Medical Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606